Abstract:Non-human primates are valuable for modelling human disorders and for developing therapeutic strategies; however, little work has been reported in establishing transgenic non-human primate models of human diseases. Huntington’s disease (HD) is an autosomal dominant neurodegenerative disorder characterized by motor impairment, cognitive deterioration and psychiatric disturbances followed by death within 10–15 years of the onset of the symptoms1, 2, 3, 4. HD is caused by the expansion of cytosine-adenine-guanine (CAG, translated into glutamine) trinucleotide repeats in the first exon of the human huntingtin (HTT) gene5. Mutant HTT with expanded polyglutamine (polyQ) is widely expressed in the brain and peripheral tissues2, 6, but causes selective neurodegeneration that is most prominent in the striatum and cortex of the brain. Although rodent models of HD have been developed, these models do not satisfactorily parallel the brain changes and behavioural features observed in HD patients. Because of the close physiological7, neurological and genetic similarities8, 9 between humans and higher primates, monkeys can serve as very useful models for understanding human physiology and diseases10, 11. Here we report our progress in developing a transgenic model of HD in a rhesus macaque that expresses polyglutamine-expanded HTT. Hallmark features of HD, including nuclear inclusions and neuropil aggregates, were observed in the brains of the HD transgenic monkeys. Additionally, the transgenic monkeys showed important clinical features of HD, including dystonia and chorea. A transgenic HD monkey model may open the way to understanding the underlying biology of HD better, and to the development of potential therapies. Moreover, our data suggest that it will be feasible to generate valuable non-human primate models of HD and possibly other human genetic diseases.

Towards a transgenic model of Huntington|[rsquo]|s disease in a non-human primate

Towards a transgenic model of Huntington’s disease in a non-human primate

Longitudinal Transcriptomic Dysregulation in the Peripheral Blood of Transgenic Huntington’s Disease Monkeys

Transgenic Animal Models for Study of the Pathogenesis of Huntington&rsquo;s Disease and Therapy

A novel rhesus macaque model of Huntington’s disease recapitulates key neuropathological changes along with progressive motor and cognitive decline

Transgenic animal models for study of the pathogenesis of Huntington's disease and therapy.

Expression of mutated huntingtin fragment in the putamen is sufficient to produce abnormal movement in non-human primates.

Progressive Cognitive Deficit, Motor Impairment and Striatal Pathology in a Transgenic Huntington Disease Monkey Model from Infancy to Adulthood

Generation of Rhesus Macaque Embryos with Expanded CAG Trinucleotide Repeats in the Huntingtin Gene

Accumulation of N-terminal Mutant Huntingtin in Mouse and Monkey Models Implicated As a Pathogenic Mechanism in Huntington's Disease

A Non-Human Primate Model with Alzheimer's Disease-Like Pathology Induced by Hippocampal Overexpression of Human Tau

Progress in studies of gene therapy for Huntington's disease

A nonhuman primate model with Alzheimer's disease-like pathology induced by hippocampal overexpression of human tau

Neuropathology of Transgenic HD Animal Models

Cas9-mediated Replacement of Expanded CAG Repeats in a Pig Model of Huntington’s Disease

Cas9-mediated replacement of expanded CAG repeats in a pig model of Huntington's disease

Expression of mutant exon 1 huntingtin fragments in human neural stem cells and neurons causes inclusion formation and mitochondrial dysfunction

Opportunities and challenges in modeling human brain disorders in transgenic primates

Large Animal Models of Huntington's Disease.

Genetically Modified Non-Human Primate Models for Research on Neurodegenerative Diseases.

Use of human stem cells in Huntington disease modeling and translational research